Human papillomavirus detection by PCR assay in a large series of high-grade squamous intraepithelial lesions with cytohistological correlation and follow-up

Acta Cytologica

Volumn 55, Issue 5, 2011, Pages 426-432

  Lerma Puertas, Enrique ^a   Otal Salaverri, Concepción ^b   Ríos Martín, Juan José ^b   Sánchez Gómez, Ana ^b   Jiménez Caraballo, Antonio ^b   González Cámpora, Ricardo ^b  

^a Hospital Sant Pau   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Bethesda System; Cervical carcinoma; Cervical intraepithelial neoplasia; Dysplasia; High grade squamous intraepithelial lesion; Human papillomavirus

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; COLPOSCOPY; DIAGNOSTIC ACCURACY; DOWN REGULATION; FOLLOW UP; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 6; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MICROINVASIVE SQUAMOUS CARCINOMA; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS STRAIN; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 80155175033     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000330810     Document Type: Article

References (46)

1. Waggoner SE: Cervical cancer. Lancet 2003; 361: 2217-2225.
2. Klinkhamer PJ, Meerding WJ, Rosier PF, Hanselaar AG: Liquid-based cervical cytology. Cancer 2003; 99: 263-271.
3. Koss LG: The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA 1989; 261: 737-743.
4. Renshaw AA: Measuring sensitivity in gynaecologic cytology: a review. Cancer 2002; 96: 210-217.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
6. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
7. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A, von Knebel Doeberitz M: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008; 68: 307-313.
8. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M: Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer 1994; 69: 167-171.
9. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999; 341: 1633-1638.
10. Mantovani F, Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-7887.
11. Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, Shroyer KR: Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004; 35: 689-696.
12. Food and Drug Administration: http://wwwaccessdatafda.gov/cdrh-docs/pdf/ p890064s009a.pdf (accessed March 31, 2003).
13. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA: Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002; 288: 1749-1757.
14. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, Mun MS, Kim SH, Jeong JK: Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003; 97: 1672-1680.
15. Kurman RJ, Solomon D: The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses. N.Y., Springer, 2003.
16. National Comprehensive Cancer Network:NCCN cervical cancer screening. 2010. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
17. IARC: Cervical Cancer Screening. IARC Handbooks of Cancer Prevention. Lyon, IARC Press, 2005.
18. Guido R, Schiffman M, Solomon D, Burke L: Postcolposcopy management strategies for women referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188: 1401-1405.
19. Centers for Disease Control and Prevention: Sexually transmitted diseases - interactive data 1996-2008. 2011. http://www.cdc.gov/std/hpv/default.htm.
20. Lerma E, Quintana MJ, Quilez M, Esteva E,Carreras A, Bonfill X, Prat J, Calaf J: Effectiveness of liquid-based cytology and Papanicolaou tests in a low risk population. Acta Cytol 2007; 51: 399-406.
21. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C: American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362.
22. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, Desai M, Mather J, Moss S, Roberts C, Kitchener HC: Prevalence of type-specific HPV infection by age and gradeof cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008; 98: 1704-1709.
23. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.
24. Moscicki AB, Schiffman M, Kjaer S, Villa LL: Updating the natural history of HPV and anogenital cancer. Vaccine 2006; 24(suppl 3):S3/42-51.
25. Lee YH, Kim YR, Ji JD, Sohn J, Song GG: Fas promoter-670 polymorphism is associated with development of anti-RNP antibodies in systemic lupus erythematosus. J Rheumatol 2001; 28: 2008-2011.
26. Zhang Z, Borecki I, Nguyen L, Ma D, Smith K, Huettner PC, Mutch DG, Herzog TJ, Gibb RK, Powell MA, Grigsby PW, Massad LS, Hernandez E, Judson PL, Swisher EM, Crowder S, Li J, Gerhard DS, Rader JS: CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 2007; 67: 11202-11208.
27. Lai HC, Sytwu HK, Sun CA, Yu MH, Yu CP, Liu HS, Chang CC, Chu TY: Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003; 103: 221-225.
28. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al: Humanpapillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056.
29. Wentzensen N, Vinokurova S, von Knebel Doeberitz M: Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004; 64: 3878-3884.
30. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM: A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195: 1582-1589.
31. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, Snijders PJ, Meijer CJ: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow- up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-1772.
32. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlee F, Franco EL: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588.
33. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597.
34. Ibrahim SN, Krigman HR, Coogan AC, Wax TD, Dodd LG, Bentley RC, Robboy SJ, Johnston WW: Prospective correlation of cervicovaginal cytologic and histologic specimen. Am J Clin Pathol 1996; 106: 319-324.
35. Tritz DM, Weeks JA, Spires SE, Sattich M, Banks H, Cibull ML, Davey DD: Etiologies for non-correlating cervical cytologies and biopsies. Am J Clin Pathol 1995: 103: 594-597.
36. Bewtra C, Pathan M, Hashish H: Abnormal pap smear with negative follow-up biopsies: improving cytohistological correlation. Diagn Cytopathol 2003; 29: 200-202.
37. Anschau F, Guimaraes MA: Discordance between cytology and biopsy histology of the cervix: what to consider and what to do. Acta Cytol 2011; 55: 158-162.
38. Ortiz M, Torres M, Muñoz L, Fernández-García E, Canals J, Cabornero AI, Aguilar E, Ballesteros J, Del Amo J, García-Sáiz A: Oncogenic human papillomavirus (HPV) type distribution and HPV type 16E6 variants in two Spanish population groups with different levels of HPV infection risk. J Clin Microbiol 2006; 44: 1428-1434.
39. del Amo J, González C, Losana J, Clavo P, Muñoz L, Ballesteros J, García-Saiz A, Belza MJ, Ortiz M, Menéndez B, del Romero J, Bolumar F: Influence of age and geographical origin in the prevalence of high risk human papillomavirus in migrant female sex workers in Spain. Sex Transm Infect 2005; 81: 79-84.
40. Garcia-García JA, Pérez-Vallés A, Martorell M, Gómez B, Gómez-Cabrero D, Soler F, Calabuig C: Distribution of human papillomavirus types women from Valencia, Spain, with abnormal cytology. Acta Cytol 2010; 54: 159-164.
41. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-632.
42. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE: Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101: 475-487.
43. Castellsagué X, Drudis T, Cañadas MP, Goncé A, Ros R, Pérez JM, Quintana MJ, Muñoz J, Albero G, de Sanjosé S, Bosch FX: Human papillomavirus (HPV) infection in pregnant women and mother-to-child transmission of genital HPV genotypes: a prospective study in Spain. BMC Infect Dis 2009;9:74.
44. Insinga RP, Liaw KL, Johnson LG, Madeleine MM: A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611-1622.
45. Prétet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D: Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: the EDiTH III study. Gynecol Oncol 2008;110:179-184.
46. Safaeian M, Schiffman M, Gage J, Solomon D, Wheeler CM, Castle PE: Detection of precancerous cervical lesions is differential by human papillomavirus type. Cancer Res 2009; 69: 3262-3266.